Literature DB >> 20549181

Cancer and diabetes: are we ready for prime time?

U Smith1, E A M Gale.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20549181     DOI： 10.1007/s00125-010-1815-8

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  11 in total

1.  Linking diabetes and cancer: a consensus on complexity.

Authors:  Andrew Renehan; Ulf Smith; M Sue Kirkman
Journal:  Lancet       Date:  2010-06-26       Impact factor: 79.321

2.  An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation.

Authors:  Dimitrios Iliopoulos; Heather A Hirsch; Kevin Struhl
Journal:  Cell       Date:  2009-10-29       Impact factor: 41.582

3.  Reduced screening mammography among women with diabetes.

Authors:  Lorraine L Lipscombe; Janet E Hux; Gillian L Booth
Journal:  Arch Intern Med       Date:  2005-10-10

4.  Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

Authors:  S L Bowker; Y Yasui; P Veugelers; J A Johnson
Journal:  Diabetologia       Date:  2010-04-21       Impact factor: 10.122

5.  Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study.

Authors:  L G Hemkens; U Grouven; R Bender; C Günster; S Gutschmidt; G W Selke; P T Sawicki
Journal:  Diabetologia       Date:  2009-06-30       Impact factor: 10.122

6.  Diabetes and cancer: a consensus report.

Authors:  Edward Giovannucci; David M Harlan; Michael C Archer; Richard M Bergenstal; Susan M Gapstur; Laurel A Habel; Michael Pollak; Judith G Regensteiner; Douglas Yee
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

7.  The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.

Authors:  C J Currie; C D Poole; E A M Gale
Journal:  Diabetologia       Date:  2009-07-02       Impact factor: 10.122

Review 8.  Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis.

Authors:  Bethany B Barone; Hsin-Chieh Yeh; Claire F Snyder; Kimberly S Peairs; Kelly B Stein; Rachel L Derr; Antonio C Wolff; Frederick L Brancati
Journal:  JAMA       Date:  2008-12-17       Impact factor: 56.272

9.  Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden.

Authors:  J M Jonasson; R Ljung; M Talbäck; B Haglund; S Gudbjörnsdòttir; G Steineck
Journal:  Diabetologia       Date:  2009-07-09       Impact factor: 10.122

10.  Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group.

Authors:  H M Colhoun
Journal:  Diabetologia       Date:  2009-07-15       Impact factor: 10.122
View more
  23 in total

1.  When Anti-Aging Studies Meet Cancer Chemoprevention: Can Anti-Aging Agent Kill Two Birds with One Blow?

Authors:  Noriko N Yokoyama; Andria Denmon; Edward M Uchio; Mark Jordan; Dan Mercola; Xiaolin Zi
Journal:  Curr Pharmacol Rep       Date:  2015-04-14

Review 2.  The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis.

Authors:  H-D Wu; J-J Zhang; B-J Zhou
Journal:  Clin Transl Oncol       Date:  2020-06-07       Impact factor: 3.405

Review 3.  Metformin in cancer prevention and therapy.

Authors:  Jacek Kasznicki; Agnieszka Sliwinska; Józef Drzewoski
Journal:  Ann Transl Med       Date:  2014-06

4.  Metformin Associated With Increased Survival in Type 2 Diabetes Patients With Pancreatic Cancer and Lymphoma.

Authors:  Anne Wynn; Albert Vacheron; Jeffrey Zuber; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2019-07-04       Impact factor: 2.378

5.  Diabetes, treatments for diabetes and their effect on cancer incidence and mortality: attempts to disentangle the web of associations.

Authors:  S H Wild
Journal:  Diabetologia       Date:  2011-05-04       Impact factor: 10.122

6.  Metformin reduces serum CA199 levels in type 2 diabetes Chinese patients with time-effect and gender difference.

Authors:  Dandan Zhang; Wolin Hou; Fang Liu; Jun Yin; Wei Lu; Ming Li; Taishan Zheng; Fengdi Lu; Yuqian Bao; Weiping Jia
Journal:  Diabetes Technol Ther       Date:  2014-12-30       Impact factor: 6.118

7.  The influence of diabetes severity on receipt of guideline-concordant treatment for breast cancer.

Authors:  Susan A Sabatino; Trevor D Thompson; Xiao-Cheng Wu; Steven T Fleming; Gretchen G Kimmick; Amy Trentham-Dietz; Rosemary Cress; Roger T Anderson
Journal:  Breast Cancer Res Treat       Date:  2014-06-05       Impact factor: 4.872

8.  Metformin Has a Positive Therapeutic Effect on Prostate Cancer in Patients With Type 2 Diabetes Mellitus.

Authors:  R William Chong; Vijaya Vasudevan; Jeffrey Zuber; Solomon S Solomon
Journal:  Am J Med Sci       Date:  2016-01-29       Impact factor: 2.378

9.  PTEN mutations as a cause of constitutive insulin sensitivity and obesity.

Authors:  Aparna Pal; Thomas M Barber; Martijn Van de Bunt; Simon A Rudge; Qifeng Zhang; Katherine L Lachlan; Nicola S Cooper; Helen Linden; Jonathan C Levy; Michael J O Wakelam; Lisa Walker; Fredrik Karpe; Anna L Gloyn
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

Review 10.  Animal models of GWAS-identified type 2 diabetes genes.

Authors:  Gabriela da Silva Xavier; Elisa A Bellomo; James A McGinty; Paul M French; Guy A Rutter
Journal:  J Diabetes Res       Date:  2013-04-11       Impact factor: 4.011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.